1-2 of 2
Jimmy L. Zhao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Jimmy L. Zhao, Karim Fizazi, Fred Saad, Kim N. Chi, Mary-Ellen Taplin, Cora N. Sternberg, Andrew J. Armstrong, Johann S. de Bono, William T. Duggan, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 860–869.
https://doi.org/10.1158/1078-0432.CCR-21-1090
Published: 01 March 2022
View article titled, The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Open the PDF for The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Landon C. Brown, Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, Ethan S. Barnett, Emily A. Carbone, Jimmy L. Zhao, Patrick Healy, Monika Anand, Audrey Gill, Adam Jendrisak, William R. Berry, Santosh Gupta, Simon G. Gregory, Richard Wenstrup, Emmanuel S. Antonarakis, Daniel J. George, Howard I. Scher, Andrew J. Armstrong
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 4077–4088.
https://doi.org/10.1158/1078-0432.CCR-20-3471
Published: 15 July 2021
View article titled, Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Open the PDF for Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide in another window
Includes: Supplementary data